超过40%的癌症患者在接受抗癌治疗时使用补充和替代药物。

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Maurien D Rombouts, Rowan M Y Karg, Shiewanie S P Raddjoe, Mirjam Crul
{"title":"超过40%的癌症患者在接受抗癌治疗时使用补充和替代药物。","authors":"Maurien D Rombouts, Rowan M Y Karg, Shiewanie S P Raddjoe, Mirjam Crul","doi":"10.1136/ejhpharm-2024-004264","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of complementary and alternative medications (CAM) is popular among cancer patients. CAM includes vitamins, minerals, phytotherapy, homeopathy, nutritional supplements and probiotics. CAM use may lead to unwanted risks by interacting with anticancer drugs; therefore, it is important for healthcare providers to be aware of CAM use by their patients. This article describes the prevalence and potential risk of CAM use in an adult Dutch cancer population. This is the first study in which CAM use was investigated using medication reconciliation.</p><p><strong>Methods: </strong>A descriptive, observational study was conducted at Amsterdam UMC between August 2021 and July 2022. Data regarding the use of CAM was obtained by medication reconciliation reviews with inpatients and outpatients with cancer who received systemic anticancer treatment. Acquired data were evaluated by the research team, and the risks of interactions were classified into relevant, potential, unknown or no interaction. Ultimately, patient-specific recommendations on the use of CAM were provided.</p><p><strong>Results: </strong>Of the 100 included patients, 73% used CAM during the past year and 41% used CAM actively while receiving anticancer treatment. The most common CAM were vitamins and multivitamins (both 28%). Some 10% of CAM were classified as having a relevant interaction with one or more concurrently used anticancer drugs. No association between age or gender and CAM use was found, while outpatients used significantly more CAM than inpatients (72.7% vs 32.1%; p=0.001). Patients received personalised advice from the hospital pharmacy about their CAM use.</p><p><strong>Conclusions: </strong>More than 40% of oncology patients investigated in this study used CAM while receiving anticancer treatment, leading to unwanted risks. This prevalence is higher than reported in other studies, possibly due to the use of medication reconciliation interviews. To guarantee safety and efficacy of anticancer treatment, communication between healthcare professionals and patients about CAM is essential.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Over 40% of cancer patients use complementary and alternative medications while receiving anticancer treatment.\",\"authors\":\"Maurien D Rombouts, Rowan M Y Karg, Shiewanie S P Raddjoe, Mirjam Crul\",\"doi\":\"10.1136/ejhpharm-2024-004264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The use of complementary and alternative medications (CAM) is popular among cancer patients. CAM includes vitamins, minerals, phytotherapy, homeopathy, nutritional supplements and probiotics. CAM use may lead to unwanted risks by interacting with anticancer drugs; therefore, it is important for healthcare providers to be aware of CAM use by their patients. This article describes the prevalence and potential risk of CAM use in an adult Dutch cancer population. This is the first study in which CAM use was investigated using medication reconciliation.</p><p><strong>Methods: </strong>A descriptive, observational study was conducted at Amsterdam UMC between August 2021 and July 2022. Data regarding the use of CAM was obtained by medication reconciliation reviews with inpatients and outpatients with cancer who received systemic anticancer treatment. Acquired data were evaluated by the research team, and the risks of interactions were classified into relevant, potential, unknown or no interaction. Ultimately, patient-specific recommendations on the use of CAM were provided.</p><p><strong>Results: </strong>Of the 100 included patients, 73% used CAM during the past year and 41% used CAM actively while receiving anticancer treatment. The most common CAM were vitamins and multivitamins (both 28%). Some 10% of CAM were classified as having a relevant interaction with one or more concurrently used anticancer drugs. No association between age or gender and CAM use was found, while outpatients used significantly more CAM than inpatients (72.7% vs 32.1%; p=0.001). Patients received personalised advice from the hospital pharmacy about their CAM use.</p><p><strong>Conclusions: </strong>More than 40% of oncology patients investigated in this study used CAM while receiving anticancer treatment, leading to unwanted risks. This prevalence is higher than reported in other studies, possibly due to the use of medication reconciliation interviews. To guarantee safety and efficacy of anticancer treatment, communication between healthcare professionals and patients about CAM is essential.</p>\",\"PeriodicalId\":12050,\"journal\":{\"name\":\"European journal of hospital pharmacy : science and practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of hospital pharmacy : science and practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2024-004264\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-004264","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:补充和替代药物(CAM)的使用在癌症患者中很流行。CAM包括维生素、矿物质、植物疗法、顺势疗法、营养补充剂和益生菌。CAM的使用可能会与抗癌药物相互作用,从而导致不必要的风险;因此,对于医疗保健提供者来说,了解患者使用辅助治疗是很重要的。这篇文章描述了荷兰成年癌症人群中CAM使用的流行程度和潜在风险。这是第一个使用药物和解来调查CAM使用的研究。方法:2021年8月至2022年7月在阿姆斯特丹UMC进行了一项描述性观察性研究。有关CAM使用的数据是通过对接受全身抗癌治疗的住院和门诊癌症患者的药物调和评价获得的。研究小组对获得的数据进行评估,并将相互作用的风险分为相关、潜在、未知或无相互作用。最后,提供了针对具体患者使用辅助治疗的建议。结果:在100例纳入的患者中,73%的患者在过去一年中使用了CAM, 41%的患者在接受抗癌治疗时积极使用CAM。最常见的辅助维生素是维生素和多种维生素(均为28%)。大约10%的CAM被归类为与一种或多种同时使用的抗癌药物有相关的相互作用。年龄和性别与辅助治疗的使用没有关联,但门诊患者使用辅助治疗的比例明显高于住院患者(72.7% vs 32.1%;p = 0.001)。患者从医院药房获得了有关其CAM使用的个性化建议。结论:在本研究中,超过40%的肿瘤患者在接受抗癌治疗时使用了CAM,这导致了不必要的风险。这一患病率高于其他研究报告,可能是由于使用了药物和解访谈。为了保证抗癌治疗的安全性和有效性,医护人员与患者之间关于辅助化疗的沟通至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Over 40% of cancer patients use complementary and alternative medications while receiving anticancer treatment.

Background: The use of complementary and alternative medications (CAM) is popular among cancer patients. CAM includes vitamins, minerals, phytotherapy, homeopathy, nutritional supplements and probiotics. CAM use may lead to unwanted risks by interacting with anticancer drugs; therefore, it is important for healthcare providers to be aware of CAM use by their patients. This article describes the prevalence and potential risk of CAM use in an adult Dutch cancer population. This is the first study in which CAM use was investigated using medication reconciliation.

Methods: A descriptive, observational study was conducted at Amsterdam UMC between August 2021 and July 2022. Data regarding the use of CAM was obtained by medication reconciliation reviews with inpatients and outpatients with cancer who received systemic anticancer treatment. Acquired data were evaluated by the research team, and the risks of interactions were classified into relevant, potential, unknown or no interaction. Ultimately, patient-specific recommendations on the use of CAM were provided.

Results: Of the 100 included patients, 73% used CAM during the past year and 41% used CAM actively while receiving anticancer treatment. The most common CAM were vitamins and multivitamins (both 28%). Some 10% of CAM were classified as having a relevant interaction with one or more concurrently used anticancer drugs. No association between age or gender and CAM use was found, while outpatients used significantly more CAM than inpatients (72.7% vs 32.1%; p=0.001). Patients received personalised advice from the hospital pharmacy about their CAM use.

Conclusions: More than 40% of oncology patients investigated in this study used CAM while receiving anticancer treatment, leading to unwanted risks. This prevalence is higher than reported in other studies, possibly due to the use of medication reconciliation interviews. To guarantee safety and efficacy of anticancer treatment, communication between healthcare professionals and patients about CAM is essential.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信